ADDvise signs a new agreement with Laborie with a total order value of at least MSEK 50 - Regulatory information

05-03-2020   Regulatory press release

ADDvise Group AB (publ)’s subsidiary Sonesta Medical AB signs a new agreement with Laborie Medical Technologies (“Laborie) granting Laborie the right to sell Sonesta Medical’s urology- and gynecology chairs and video fluoroscopy tables (the “Products”) in all countries in the world with an exclusive right to distribution in USA and France, United Kingdom, Ireland, Germany, Belgium, Netherlands, Austria, Switzerland and Luxembourg (the “Exclusive Markets”). The initial term of the agreement is three years. The total value of the orders during the initial term of the agreement is at least MSEK 50.

In accordance with the agreement the parties have agreed upon minimum volumes for the distribution in the Exclusive Markets, entailing that Laborie shall in total order at least 165 Products per year, whereof at least 20 of these units shall be video fluoroscopy tables.

Laborie is a company based in Canada and a leading global developer, manufacturer and marketer of medical technology and consumables used for diagnostic and therapeutic solutions in urology, urogynecology and gastroenterology.

“Laborie is an existing customer to the group. I am proud to get additional order volumes from Laborie which will strengthen our relationship”, says Rikard Akhtarzand, CEO, ADDvise Group AB.


For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 5 March 2020 at 09.45 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50,, is the Company's Certified Adviser. Additional information is available at


Latest press releases

ADDvise announces preliminary result for 2022 which is stronger than expected


The preliminary result for ADDvise Group for the full year 2022 significantly deviates from what ADDvise Group considers to be current market expectations. [image] The net sales pro forma full year 2022 rolling 12 months amounted to SEK 1,097 million with an adjusted EBITDA pro forma of SEK 241 million. The financial targets for the…

ADDvise receives order worth USD 3.5 million


ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from AxisCare Health Logistics Inc, a company distributing equipment and medical supplies to hospitals, clinics, medical offices and medical equipment suppliers. The order is worth approximately USD 3.5 million. The order consists of delivery of the prescription dietary supplemental Folite, developed and manufactured by…

ADDvise receives order worth USD 1.8 million


ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Nasser Saeed Al Hajri & Partners Contracting (NHS & Partners), a leading construction contractor in the United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves the detailed design, supply and installation of an ISO 8 and ISO 7…